Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
about
Novel Drugs in Follicular LymphomaWhen to treat patients with relapsed follicular lymphoma.Reappraising the timing of transplant for indolent non-Hodgkin lymphomas.Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.The clinical development of obinutuzumab for the treatment of follicular lymphoma.Immunotherapy in hematologic malignancies: past, present, and future.Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape.Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas.Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.Follicular Lymphoma: The Management of Elderly Patient.Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone.A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapyPharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Obinutuzumab: A Review in Rituximab-Refractory or -Relapsed Follicular Lymphoma.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells.Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.The role of novel immunotherapies in non-Hodgkin lymphoma.Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: a NLCS and CIBMTR Analysis.Podocalyxin promotes proliferation and survival in mature B-cell non-Hodgkin lymphoma cells.Follicular lymphoma: 2018 update on diagnosis and management.Title: Rituximab: A Benchmark in the Development of Chemotherapy-free Treatment Strategies for Follicular Lymphomas.The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma.Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.Obinutuzumab for the treatment of chronic lymphocytic leukemia and other B-cell lymphoproliferative disorders.Combination therapy with the type II anti-CD20 antibody obinutuzumab.MRD-negative complete remission in relapsed refractory hairy cell leukemia with bendamustine and obinutuzumab.Chemotherapy-free, triple combination of obinutuzumab, venetoclax and idasanutlin: antitumor activity in xenograft models of non-Hodgkin lymphoma.Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.The evolving role of targeted biological agents in the management of indolent B-cell lymphomas.The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.Randomized phase II study of a bendamustine monotherapy schedule for relapsed or refractory low-grade B-cell non-Hodgkin lymphoma or mantle cell lymphoma (RABBIT-14).Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).Tumor-Targeting Anti-CD20 Antibodies Mediate In Vitro Expansion of Memory Natural Killer Cells: Impact of CD16 Affinity Ligation Conditions and In Vivo Priming.
P2860
Q28076335-0B59A0F5-C558-4803-AEE1-1591EE649ECEQ30238528-5D0CB3E3-D6C6-40C0-A6E4-62555C79A196Q30248407-C3FF1762-CB60-46C6-9218-98CAFB26146FQ30252598-C800E4CB-2DE9-4FDD-9B9A-4D18A0CC59DDQ33565265-DFC273F6-0F78-476B-87C4-FF0E51F5F6F0Q33593865-8EB78C07-A0C0-4BD7-A361-4E4CF0F92DBCQ33621041-A0E83FA9-AA5D-47CB-A4DE-36DD07AF9AEEQ33780903-0A248EC2-BDDC-4A51-B964-DF42A7831830Q37524930-6D6F6D4C-71C5-4ECB-BD66-F5F790FFF82AQ37577856-2CFCFC49-8D02-488E-BED3-50526A584D63Q37580867-F03E5972-BC87-4F46-8360-B79C2327F6C2Q37672472-79DD6E3A-484B-4F1F-B553-ECF31872779CQ37741570-3A6C68EE-C0FB-4E32-98AF-CD792680C89BQ38759420-4FBCE643-BF23-4128-A549-34EAF4F8F828Q38818283-30CBBC3A-3F3E-4C82-9998-9BC1CD2CD0FCQ38889978-562F061E-B5F6-4322-9E54-615973C80030Q39091822-32B79BF5-243B-40FB-BD11-41BB544AE247Q39110347-3FDA6AC1-B6BE-4286-9E77-6F80E133977AQ39279968-73EBC81F-D99B-4A1A-8E17-D6348A9CBCA2Q41000160-B22F0220-DB41-492E-8940-9DD3D796DA88Q41695080-ABF7C849-BE8A-4D94-A708-8804F5F40562Q45875848-0CDD2FBC-557E-4D58-A6FC-DBE08E8295FCQ46238878-58AC7138-E919-4F2C-B19D-8FB50F3007CDQ47219215-DA8B51D1-28C8-4209-8374-E8559FF7F854Q47365893-E609C271-7E17-48ED-ACF4-85F2691AB24BQ47563526-91D26B1D-8832-42B8-8BE0-C36D1C770E4FQ47564275-7771475F-2F71-4287-BA3A-9690AA63CC2FQ47688545-D4960295-BB5F-4579-B3BB-B6BA34AA68F3Q47898168-3EA0B09D-9ED1-4AC8-80F2-E48F296969CEQ48334420-2B06CDE9-0F65-4FD7-B93E-121A807C8BD3Q48339554-0BEAD332-D732-4959-B433-E76DD9997728Q48362683-9C61F702-F0E9-4475-B90B-DE318E36D069Q48557692-8EC7800E-17B8-4738-A749-6938662E553DQ49168895-AB6B8DA4-8800-44AA-81E8-9D05C03D1AA0Q49226138-1B179120-8E2C-4201-B811-924B2C51BC0CQ49914090-0CC82275-49BA-45FF-849A-7C96DFA70711Q50187344-409DF270-3989-45BD-B7F9-5B906A6AE727Q52599792-266D8BA2-B330-4236-BB2E-74FFF330BFF9Q52603250-51705D37-5066-46F9-A45A-557954E6CE42Q55486099-263042F6-E4E2-47B8-A238-E1966D042733
P2860
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Obinutuzumab plus bendamustine ...... l, multicentre, phase 3 trial.
@ast
Obinutuzumab plus bendamustine ...... l, multicentre, phase 3 trial.
@en
type
label
Obinutuzumab plus bendamustine ...... l, multicentre, phase 3 trial.
@ast
Obinutuzumab plus bendamustine ...... l, multicentre, phase 3 trial.
@en
prefLabel
Obinutuzumab plus bendamustine ...... l, multicentre, phase 3 trial.
@ast
Obinutuzumab plus bendamustine ...... l, multicentre, phase 3 trial.
@en
P2093
P50
P1433
P1476
Obinutuzumab plus bendamustine ...... l, multicentre, phase 3 trial.
@en
P2093
Anne Lennard
Bruce D Cheson
Elisabeth Wassner-Fritsch
Gregg Dueck
Günter Fingerle-Rowson
Jiri Mayer
John Gribben
Kamal Bouabdallah
Laurie H Sehn
Natalie Dimier
P304
P356
10.1016/S1470-2045(16)30097-3
P577
2016-06-23T00:00:00Z